Stem Cells & Perinatal Therapies · Professional series · EN
Stem Cells & Perinatal Therapies
Very promising science. Product-specific evidence. A higher standard of clinical judgment.
From immune-directed research to tissue repair, cell-based medicine opens important possibilities. The question is which defined product may help which clinical problem, on what evidence, and under what conditions.
SELECT YOUR QUESTION
Choose a clinical route
Follow the indication, then compare product identity, study design and the outcome that matters.
Rheumatology
Immune-directed research and established high-intensity transplantation are different clinical conversations.
- Hematopoietic transplantation in rheumatology: a different level of intervention
- MSC therapy in rheumatoid arthritis: promising research, not a shortcut around diagnosis
- Lupus and lupus nephritis: a strong rationale needs controlled clinical answers
- Beyond RA and lupus: Sjögren’s, psoriasis, and other autoimmune disease
Musculoskeletal repair
Ask whether the outcome is relief, function or demonstrated tissue repair.
Function, frailty & aging
Define the outcome and the limitations before interpreting a signal.
Aesthetic medicine
Connect the tissue goal to a defined product, procedure and patient context.
FOR PATIENTS & FAMILIES
Keep the promise. Ask better questions.
A complete guide to the proposed product, the applicable evidence, the limits and the questions to bring to an independent consultation.
ORIENT THE EVIDENCE
Begin with the fundamentals
Four short routes into the core questions behind a responsible clinical recommendation.
Know what the product is
Cell origin and processing change the question.
Ask how quality is shown
Characterization, manufacturing and traceability matter.
Read the safety signal
Follow-up matters as much as the initial response.
Visit the evidence desk
Read the design, result and limitations together.
PROFESSIONAL COLLECTION · EN
Explore every article
Browse by theme or search for a condition, product or clinical question.
21 articles
Foundations
Stem cells: why the promise deserves precision
An optimistic introduction without treating a diverse scientific field as a single treatment.
HSCs, MSCs, BMAC, SVF: a vocabulary that changes decisions
The labels on a brochure are not enough to identify the biological intervention.
Umbilical cord and placental therapies: the source is not the treatment
Cord blood, Wharton’s jelly, placental membranes, and extracts need separate evidence pathways.
Immunomodulation and repair: what might the cells actually do?
Why a sophisticated mechanism is a starting point, not the final clinical answer.
The next frontier: what could make cell therapy genuinely transformative
An author’s research agenda for turning biological promise into reproducible clinical value.
Rheumatology
Hematopoietic transplantation in rheumatology: a different level of intervention
Selected systemic sclerosis care must not be confused with retail regenerative infusions.
MSC therapy in rheumatoid arthritis: promising research, not a shortcut around diagnosis
Interpret early biological signals and long-term follow-up without confusing inflammation, damage, and pain.
Lupus and lupus nephritis: a strong rationale needs controlled clinical answers
What early trials and the 2026 real-world report can—and cannot—tell a person with refractory disease.
Beyond RA and lupus: Sjögren’s, psoriasis, and other autoimmune disease
Keep the immune hypothesis open without transporting an indication from one disease to another.
Musculoskeletal repair
Osteoarthritis and cartilage: symptom relief is not the same as regeneration
Positive small studies, a larger randomized trial, and the importance of the structural endpoint.
Tendons, ligaments, spine, and rehabilitation: match the target to the intervention
A framework for evaluating regenerative proposals outside the main arthritis trials.
Functional medicine & aging
Functional medicine, frailty, and longevity: define what “better” means
New human research is worth attention without turning selected frailty findings into universal rejuvenation.
Placental extracts: a separate subject within perinatal medicine
How to discuss a biologically complex preparation without mislabeling it as living-cell therapy.
Aesthetic medicine
Cell-based and perinatal approaches in aesthetic medicine
Keep skin biology, visible outcomes, tissue repair, and systemic disease in the same clinical conversation.
Clinical judgment
Product quality: the science hidden behind the vial
Identity, viability, potency, release testing, and traceability are part of the treatment—not administrative extras.
Approval, authorization, registration: words that are not interchangeable
A United States–focused framework with a dated European example.
Safety, uncertainty, and follow-up: compare the right risks
Neither “natural” nor “experimental” is a complete risk assessment.
Why the quality of the recommendation matters as much as the procedure
A high-level consultation integrates disease expertise, cell biology, evidence appraisal, and responsibility for the outcome.
Related—but separate
PRP and exosomes: related ideas, separate therapies
A boundary chapter, not a substitute for their own indication-specific evidence reviews.
Evidence & practical review
The evidence desk: important findings through September 25, 2026
A dated, selective review of primary studies and official regulatory records—not an exhaustive systematic review.
Before you decide: the independent consultation planner
A printable way to organize a proposal without turning a checklist into medical clearance.
RELATED FIELDS · DISTINCT EVIDENCE
Keep the therapies separate.
PRP and extracellular vesicles/exosomes require their own product- and indication-specific assessment. CAR-T is engineered immune-cell therapy.